Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 39 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
LISA PHARMA from Ukkel, company number BE0650896031, closed financial year 2025 with a result of € 25,740 after tax. For that financial year LISA PHARMA recorded a gross margin of € 109,350 and equity of € 153,372. Compared with financial year 2024, the result moved from € 66,845 to € 25,740. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 28, 2026.
€ 153,372
▲ 20% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 25,740
▼ 61% vs 2024
Profit after tax over the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 134,822.
People and assets in 2025
€ 51,030
▼ 20% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 8,185
▼ 10% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 201,290
▼ 23% vs 2024
€ 87,673 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 189,787
▲ 53% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 28,374
▲ 126% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 209,584 | € 160,782 | € 173,043 | € 109,350 | ▼ 37% |
| Profit after taxes | € 45,958 | € 25,538 | € 66,845 | € 25,740 | ▼ 61% |
| Equity | € 35,407 | € 60,787 | € 127,632 | € 153,372 | ▲ 20% |
| Total debts | € 575,286 | € 433,140 | € 414,107 | € 443,695 | ▲ 7% |
| Cash | € 30,536 | € 3,530 | - | - | |
| Land & buildings | € 228,241 | € 213,624 | € 199,007 | € 184,390 | ▼ 7% |
| Retained profit | € 16,857 | € 42,237 | € 109,082 | € 134,822 | ▲ 24% |
| Bank debt | € 381,439 | € 308,160 | € 262,246 | € 201,290 | ▼ 23% |
| Balance sheet total | € 610,693 | € 493,927 | € 541,739 | € 597,067 | ▲ 10% |
By gross margin, LISA PHARMA ranks 10th of 25 companies with main activity “Detailhandel in farmaceutische producten” in Ukkel that publish figures (fiscal year 2025).
Key figures of LISA PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about LISA PHARMA the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to LISA PHARMA?
What happened at LISA PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 25,740 (▼ 61% vs 2024). filed late Source: NBB ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Vorst. KBO
In short
From € 45,958 profit in 2022 to € 25,740 profit in 2025.
Paid € 33,691 in corporate taxes since 2022.
Best year ever: 2024, with € 66,845 profit.
Management
Behind LISA PHARMA is MALEC GAFFA.
Directors
According to the 2025 annual accounts
MALEC GAFFA
GERANT
Establishments
Establishment units
Physical locations of this company
Zijdeteeltstraat 8
1180 Ukkel
Wielemans Ceuppenslaan 167
1190 Vorst
Active since 30 March 2016
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Ukkel
Same main activity (Detailhandel in farmaceutische producten), 27 active companies in Ukkel, largest first.
€ 794,215 gross margin · 2025
CONSORTIUM PHARMACEUTIQUE DE BELGIQUE
€ 381,555 gross margin · 2025
€ 372,589 gross margin · 2025
€ 353,960 gross margin · 2025
€ 343,333 gross margin · 2025
€ 240,670 gross margin · 2025
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- GAFFA Abdel Malec(oprichter) 99%
- ODDA Mouna(oprichter) 1%
Details
- Company number
- 0650.896.031
- VAT number
- BE 0650.896.031
- Registered office
- Zijdeteeltstraat 8, 1180 Ukkel
- Names & denominations
- LISA PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 30 March 2016
- Peppol
- Active · Active since 10 Feb 2026
- Activities · NACE
Detailhandel in farmaceutische producten
Overige zakelijke dienstverlening, neg